Beta-O2 is a biomedical company developing the ßO2™ subcutaneously implanted bio-artificial pancreas designed for treating insulin-dependent diabetics. This device will enable insulin dependent diabetics to live with balanced glucose levels without the frequent glucose monitoring and insulin injections.
BioControl Medical is developing next generation active implantable neurostimulation devices. Miniaturo, the Company’s first product, for treatment of all types of incontinence, was sold to American Medical Systems in 2006. BioControl’s second product is the CardioFit System, intended to treat heart failure via vagus nerve stimulation.
Can-Fite is a biopharmaceutical company with a diverse pipeline of proprietary compounds that address inflammatory, ophthalmic and liver diseases. The Company’s platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target.
IPO Tel Aviv Stock Exchange (TASE:CFBI)
Colbar develops and manufactures a range of innovative tissue engineering products based on its patented cross-linked collagen technology. Colbar’s first commercial product, Evolence, is a CE-Marked and FDA approved dermal filler for the aesthetic market.
Acquired by OrthoNeutrogena, a division of Johnson & Johnson (NYSE:JNJ)
Deep Breeze is developing non invasive, radiation-free, medical imaging solutions based on its Vibration Response Imaging technology. The FDA cleared VRIXP™ is used in clinical settings for diagnosing and monitoring respiratory disease. Future products will target the remote monitoring market.
DenX Advanced Dental Systems
DenX provides advanced image-guided technology for dental training and clinical implementation. DenX's state-of-the-art technologies enhance the quality of clinical care. The company’s 3D graphics and real-time image processing are used by leading dental institutions worldwide.
F.D. Cardio has developed a technology platform to facilitate catheter use for interventional cardiology and neurology. The system provides surgeons with pushing force and maneuverability capabilities in the front distal therapeutic part of the catheter, enabling treatment of previously unreachable lesions.
Florence Medical has developed advanced cardiovascular systems for evaluation of the hemodynamic status of diseased arteries. The system provides clinical information that enables advanced diagnosis and treatment of coronary artery disease.
GeneGrafts is developing a technology platform for modulating excitable tissue. The technology is based on transplantation of cell grafts, isolated from the patient’s own body, that express specific ion channels. The technology will be used for the treatment of neurological disorders and cardiac arrhythmias.
MediGuide is developing an intra-body navigation solution, the Guided Medical Positioning System (gMPS™). gMPS enables highly accurate, real-time tracking of catheters and stents in interventional cardiology procedures, enabling better accuracy of stent deployment in intravascular interventions.
Acquired by St. Jude Medical (NYSE:STJ)
Medson develops ultrasound-based equipment designed to detect and image abnormalities in bones, cartilage and ligaments.
Procognia is a biotech company focused on glycobiology. The Company has developed a high-throughput lectin array based glycoanalysis platform technology. Procognia’s first application is the development of in-vitro and in-vivo cancer diagnostics, and targeted cancer therapy technologies.
QuantomiX develops and markets capsules that enable real-time analysis of wet cells and tissue biopsies in research patient care and drug discovery. With the QuantomiX QXTM capsule product line, wet samples, including cells and tissues biopsies, will be able to be examined immediately and accurately.
Regentis Biomaterials is developing innovative biodegradable hydrogels for the local repair of damaged cartilage and bone. The Company’s Gelrin™ family of hydrogels incorporates denatured fibrinogen as a crosslinking agent, which produces a unique biodegradation profile in-vivo.
ReWalk Robotics (NASDAQ:RWLK) is a commercial stage company that has developed the ReWalk™, an exoskeleton for people suffering from lower-limb disabilities. ReWalk™ is a user-initiated wearable brace support suit, that enables paralyzed people to stand, walk and climb stairs.
SightLine has developed the ColonoSight system for diagnosis and treatment of abnormalities in the large intestine. The system is comprised of the EndoSight non-fiber optic colonoscope, the disposable ColonSleeve multi-lumen tube, and the electro-pneumatic system control unit.
TransPharma is developing ViaDerm, a transdermal drug delivery system that enables the delivery and improves the effectiveness of small molecules, proteins, hormones, vaccines and other macromolecules. In 2008, Eli Lilly and TransPharma entered into a licensing and development agreement for the ViaDerm-hPTH product for the treatment of osteoporosis.
Trig Medical has developed the LaborPro™, an ultrasound-based labor and delivery monitoring system. The system provides real-time objective visual information on the exact position of the baby along the birth canal, the effectiveness of the uterine contractions and the uterine cervix opening.